Targeting transcription factors in acute myeloid leukemia.


Journal

International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 29 05 2018
accepted: 25 06 2018
revised: 12 06 2018
pubmed: 30 6 2018
medline: 7 2 2019
entrez: 30 6 2018
Statut: ppublish

Résumé

Transcription factors recognize and bind to consensus sequence elements that are specific for each transcription factor, and the transcription factors then regulate downstream gene expression. In the bone marrow, transcription factors, such as C/EBPα, PU.1, and RUNX1, control essential genes to maintain the normal hematopoietic system. Dysregulation of transcription factors caused by gene mutations, chromosomal aberrations, or aberrant expression can lead to cancer, including acute myeloid leukemia. In the past, transcription factors were not considered "druggable" targets. However, a better understanding of the pathology of malignant tumors and mechanisms of transcriptional regulation has enabled us to develop novel therapeutic strategies that target transcription factors. In this review, we focus on transcription factors that play important roles in leukemogenesis and current efforts and prospects in the development of transcriptional therapy. We believe that such a therapeutic approach will benefit patients with cancers that involve acute myeloid leukemia in the near future.

Identifiants

pubmed: 29956082
doi: 10.1007/s12185-018-2488-1
pii: 10.1007/s12185-018-2488-1
doi:

Substances chimiques

Transcription Factors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

28-34

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 16K21746
Organisme : NCI NIH HHS
ID : R01 CA169259
Pays : United States
Organisme : National Cancer Institute
ID : R01CA169259
Organisme : National Cancer Institute
ID : R21CA178301
Organisme : American Cancer Society
ID : RSG-1304701

Références

Oncogene. 2000 Mar 9;19(11):1437-47
pubmed: 10723135
Blood. 2000 Oct 15;96(8):2641-8
pubmed: 11023493
Nat Genet. 2001 Mar;27(3):263-70
pubmed: 11242107
Nat Med. 2001 Apr;7(4):444-51
pubmed: 11283671
Oncogene. 2001 Oct 25;20(48):6983-93
pubmed: 11704823
Nat Genet. 2002 Jan;30(1):48-58
pubmed: 11753385
Blood. 2002 Jul 15;100(2):483-90
pubmed: 12091339
Oncogene. 2003 Sep 18;22(40):6151-9
pubmed: 13679853
Nat Rev Cancer. 2004 May;4(5):394-400
pubmed: 15122210
Nat Genet. 2004 Jun;36(6):624-30
pubmed: 15146183
Blood. 2005 Sep 1;106(5):1590-600
pubmed: 15914556
Blood. 2006 Jun 1;107(11):4308-16
pubmed: 16469877
Nat Genet. 2008 Jan;40(1):51-60
pubmed: 17994017
Prostate. 2008 Feb 15;68(3):269-80
pubmed: 18163422
Ann Oncol. 2010 Feb;21(2):335-41
pubmed: 19633049
Nat Rev Cancer. 2009 Dec;9(12):862-73
pubmed: 19935675
Biochem Pharmacol. 2010 Sep 1;80(5):724-30
pubmed: 20450892
Genes Cancer. 2010 Jun;1(6):650-659
pubmed: 21132100
PLoS One. 2011;6(7):e22284
pubmed: 21811581
Blood. 2012 May 10;119(19):4408-18
pubmed: 22451420
Int J Cancer. 2013 Mar 15;132(6):1260-71
pubmed: 23180629
Clin Cancer Res. 2013 Apr 15;19(8):1933-40
pubmed: 23406773
Hepatology. 2014 Jan;59(1):216-27
pubmed: 23929703
J Med Chem. 2014 Feb 27;57(4):1454-72
pubmed: 24456472
Nat Rev Drug Discov. 2014 Mar;13(3):217-36
pubmed: 24577402
J Biol Chem. 2014 Jun 6;289(23):15969-78
pubmed: 24755219
Cancer Res. 2014 Oct 15;74(20):5855-65
pubmed: 25145672
Cancer Lett. 2014 Dec 1;355(1):18-24
pubmed: 25261049
J Natl Cancer Inst. 2014 Oct 11;106(12):null
pubmed: 25306215
Int J Biol Sci. 2014 Sep 13;10(10):1084-96
pubmed: 25332683
J Med Chem. 2015 Feb 12;58(3):1038-52
pubmed: 25396320
Mol Genet Metab. 2015 Mar;114(3):397-402
pubmed: 25533111
Int J Hematol. 2015 Apr;101(4):330-41
pubmed: 25753223
Cancer Chemother Pharmacol. 2015 Jul;76(1):35-46
pubmed: 25956709
J Biomol Screen. 2015 Oct;20(9):1150-9
pubmed: 26109609
Nat Chem Biol. 2015 Aug;11(8):571-578
pubmed: 26167872
Invest New Drugs. 2015 Oct;33(5):1086-92
pubmed: 26268924
Clin Cancer Res. 2016 Feb 1;22(3):746-56
pubmed: 26408402
Blood. 2016 Mar 3;127(9):1173-82
pubmed: 26631113
Toxicol Appl Pharmacol. 2016 Feb 1;292:1-7
pubmed: 26708503
Oncotarget. 2016 Feb 23;7(8):8653-62
pubmed: 26840025
Leukemia. 2016 Dec;30(12):2302-2311
pubmed: 27211267
Mol Cancer Ther. 2016 Dec;15(12):2905-2915
pubmed: 27707899
Oncogene. 2017 Sep 14;36(37):5221-5230
pubmed: 28504718
PLoS One. 2017 May 15;12(5):e0177227
pubmed: 28505160
J Clin Invest. 2017 Jun 30;127(7):2815-2828
pubmed: 28530640
J Clin Invest. 2017 Dec 1;127(12):4297-4313
pubmed: 29083320
Leukemia. 2018 Apr;32(4):882-889
pubmed: 29089643
Oncotarget. 2017 Oct 26;8(61):103626-103639
pubmed: 29262589
Gene. 2018 Jul 30;665:6-17
pubmed: 29704633
Mol Cell Biol. 1994 Aug;14(8):5558-68
pubmed: 8035830

Auteurs

Hisashi Takei (H)

Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA.
Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.

Susumu S Kobayashi (SS)

Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA. sukobaya@east.ncc.go.jp.
Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba, 277-8577, Japan. sukobaya@east.ncc.go.jp.
Harvard Stem Cell Institute, Harvard Medical School, Boston, USA. sukobaya@east.ncc.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH